Created by Livvi Harris
over 10 years ago
|
||
Question | Answer |
Fostamatinib R343 | Syk inhibitors |
Rilonacept | IL-1 trap (FOAS) |
Anakinra | Recombinant IL-1ra |
Pralnacasan | ICE inhibitor (oral) |
Verciniron | CCR9 blocker - Tc in gut for chromes |
Marimastat | TACE/MMP inhibitor (MS SE) |
NFkB inhibitors for TNFa | glucocorticoids thalidomide curcumin |
Ertanercept | TNFR Ab fusion protein |
Rituximab MEDI-155 | CD20 on Bc |
Zieluton | inhibits leukotrienes |
Infliximab | anti-TNF mAb (hu Fc & mu Fv) |
Adalimumab | Fully hu anti-TNF |
certolizumab pegol | PEGylated Fab fragment of TNFa |
PEGylation | ↑ stability ↓ renal clearnace |
Drawbacks of immunotherapy for TNFa | - immunogenic (∴ humanise) - short plasma T1/2 (∴ PEG) - need to IV admin - Infection risks (latent TB) - expensive |
Onercept | PEG TNF binding protein (discontinued) |
Ruxolitinib | JAK 1/2 inhibitor |
Tofacitinib | Orally active JAK inhibitor (RA w/ MTX) |
nedocromil | sodium cromoglycate topical for nose & eyes Mast cell stablaliser: inhibit mediator release only effective in 50% of population but treats early and late phase asthma |
prednisolone budsonide | inhibits NFkB ∴ leuk migration via chemotaxis glucocorticoids |
Altrakincept | soluable recombinant IL-4 dissapointing PIII |
Pitrakinra | IL-4 variant ↓ late phase responses |
Librikizumab | anti-IL-13 mAb effects secretion of epithelium only really helps FEV1 improvements |
Ustekinumab | hu mAb |
ketotifen | H1 antagonist & mast cell stabliser opthalmic and oral also leukotriene and PDE antagonist Maybe H4 activity: chemotaxis |
Omalizumab | anti-IgE for allergic athmatics: NICE in sterioid resistants binds Fc needs to be taken for a while and expensive |
anti-IL-4 | Altrakincept: soluable recombinant IL-4 receptor Pitrakinra: IL-4 variant |
Lebrikizumab | IL-13 mAb effects secretion of epithelium |
Mepolizumab | anti-IL5 for eosinophilic dermatis |
Braikinumab | IL-12/23 mAb |
Want to create your own Flashcards for free with GoConqr? Learn more.